|
1
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar
|
|
2
|
Kurman RJ and Shih IeM: The dualistic
model of ovarian carcinogenesis: Revisited, revised, and expanded.
Am J Pathol. 186:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alsop K, Fereday S, Meldrum C, deFazio A,
Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, et
al: BRCA mutation frequency and patterns of treatment response in
BRCA mutation-positive women with ovarian cancer: A report from the
Australian Ovarian Cancer Study Group. J Clin Oncol. 30:2654–2663.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gadducci A, Guarneri V, Peccatori FA,
Ronzino G, Scandurra G, Zamagni C, Zola P and Salutari V: Current
strategies for the targeted treatment of high-grade serous
epithelial ovarian cancer and relevance of BRCA mutational status.
J Ovarian Res. 12:92019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beck B and Blanpain C: Unravelling cancer
stem cell potential. Nat Rev Cancer. 13:727–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colak S and Medema JP: Cancer stem
cells-important players in tumor therapy resistance. FEBS J.
281:4779–4791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Munoz-Galvan S, Felipe-Abrio B,
Verdugo-Sivianes EM, Perez M, Jiménez-García MP, Suarez-Martinez E,
Estevez-Garcia P and Carnero A: Downregulation of MYPT1 increases
tumor resistance in ovarian cancer by targeting the Hippo pathway
and increasing the stemness. Mol Cancer. 19:72020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY,
Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis,
cancer stem cell phenotype, and oncogenic metabolism in cancer
cells by ionizing radiation. Mol Cancer. 16:102017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu
Y, Yao Y and Li D: The epithelial to mesenchymal transition (EMT)
and cancer stem cells: Implication for treatment resistance in
pancreatic cancer. Mol Cancer. 16:522017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng Y and Pan D: The hippo signaling
pathway in development and disease. Dev Cell. 50:264–282. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang C, Wang J, Yao M, Ji X, Shi W, Xu C,
Zeng LH and Wu X: Hippo signaling activates hedgehog signaling by
Taz-driven Gli3 processing. Cell Regen. 12:32023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu S and Tang C: The Role of ARID1A in
Tumors: Tumor initiation or tumor suppression? Front Oncol.
11:7451872021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mathur R: ARID1A loss in cancer: Towards a
mechanistic understanding. Pharmacol Ther. 190:15–23. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin M, Xu S, Li J, Li L and Tang C: Role
of ARID1A in the regulation of human trophoblast migration and
invasion. Reprod Sci. 29:2363–2373. 2022. View Article : Google Scholar
|
|
16
|
Yang Z, Li C, Fan Z, Liu H, Zhang X, Cai
Z, Xu L, Luo J, Huang Y, He L, et al: Single-cell Sequencing
Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of
human bladder cancer stem cells. Eur Urol. 71:8–12. 2017.
View Article : Google Scholar
|
|
17
|
Ding DC, Liu HW and Chu TY: Interleukin-6
from ovarian mesenchymal stem cells promotes proliferation, sphere
and colony formation and tumorigenesis of an ovarian cancer cell
line SKOV3. J Cancer. 7:1815–1823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu H, Ren Q, Yan Z, Xu S, Luo J, Wu X and
Tang C: Human HAND1 inhibits the conversion of cholesterol to
steroids in trophoblasts. J Genet Genomics. 49:350–363. 2022.
View Article : Google Scholar
|
|
19
|
Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X,
Li T, Ding CY, Huang MQ, Chen XP, Wang YT, et al: Effects of alisol
B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest,
apoptosis, migration and invasion inhibition. Phytomedicine.
23:800–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lai D, Wang F, Chen Y, Wang C, Liu S, Lu
B, Ge X and Guo L: Human ovarian cancer stem-like cells can be
efficiently killed by үδ T lymphocytes. Cancer Immunol Immunother.
61:979–989. 2012. View Article : Google Scholar
|
|
21
|
Tang C, Jin M, Ma B, Cao B, Lin C, Xu S,
Li J and Xu Q: RGS2 promotes estradiol biosynthesis by trophoblasts
during human pregnancy. Exp Mol Med. 55:240–252. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang C, Takahashi-Kanemitsu A, Kikuchi I,
Ben C and Hatakeyama M: Transcriptional Co-activator Functions of
YAP and TAZ Are inversely regulated by tyrosine phosphorylation
status of parafibromin. iScience. 1:1–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Jin M, Cao B, Lin C, Li J, Xu Q, Ren Q, Xu
S and Tang C: Tianma gouteng decoction exerts pregnancy-protective
effects against preeclampsia via regulation of oxidative stress and
NO Signaling. Front Pharmacol. 13:8490742022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akrida I, Bravou V and Papadaki H: The
deadly cross-talk between Hippo pathway and epithelial-mesenchymal
transition (EMT) in cancer. Mol Biol Rep. 49:10065–10076. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu M, Hu Y, Lan T, Guan KL, Luo T and Luo
M: The Hippo signalling pathway and its implications in human
health and diseases. Signal Transduct Target Ther. 7:3762022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Liu S, Heallen T and Martin JF:
The Hippo pathway in the heart: Pivotal roles in development,
disease, and regeneration. Nat Rev Cardiol. 15:672–684. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Q, Stel WV, Noord VEV, Leegwater H,
Coban B, Elbertse K, Pruijs JTM, Béquignon OJM, Westen GV, Dévédec
SEL and Danen EHJ: Hypoxia Triggers TAZ Phosphorylation in Basal A
Triple Negative Breast Cancer Cells. Int J Mol Sci. 23:101192022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokoyama Y, Matsushita Y, Shigeto T,
Futagami M and Mizunuma H: Decreased ARID1A expression is
correlated with chemoresistance in epithelial ovarian cancer. J
Gynecol Oncol. 25:58–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De P and Dey N: Mutation-Driven Signals of
ARID1A and PI3K pathways in ovarian carcinomas: Alteration is an
opportunity. Int J Mol Sci. 20:57322019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dey A, Varelas X and Guan KL: Targeting
the Hippo pathway in cancer, fibrosis, wound healing and
regenerative medicine. Nat Rev Drug Discov. 19:480–494. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cunningham R and Hansen CG: The Hippo
pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in
cancer. Clin Sci (Lond). 136:197–222. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo
SC, Kim KH, Yoon MS, Suh DS and Kim JH: TAZ mediates
lysophosphatidic acid-induced migration and proliferation of
epithelial ovarian cancer cells. Cell Physiol Biochem. 32:253–263.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei X, Jia Y, Lou H, Ma J, Huang Q, Meng
Y, Sun C, Yang Z, Li X, Xu S, et al: Targeting YAP suppresses
ovarian cancer progression through regulation of the PI3K/Akt/mTOR
pathway. Oncol Rep. 42:2768–2776. 2019.PubMed/NCBI
|
|
35
|
Chang L, Azzolin L, Di Biagio D, Zanconato
F, Battilana G, Lucon Xiccato R, Aragona M, Giulitti S, Panciera T,
Gandin A, et al: The SWI/SNF complex is a mechanoregulated
inhibitor of YAP and TAZ. Nature. 563:265–269. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Chen X, Qiao X, Xie Y, Guo D, Li
B, Cao J, Tao Z and Hu X: Chromatin Remodelling Molecule ARID1A
determines metastatic heterogeneity in triple-negative breast
cancer by competitively binding to YAP. Cancers (Basel).
15:24472023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma S, Meng Z, Chen R and Guan KL: The
hippo pathway: Biology and pathophysiology. Annu Rev Biochem.
88:577–604. 2019. View Article : Google Scholar
|
|
38
|
Huang Z, Zhou JK, Wang K, Chen H, Qin S,
Liu J, Luo M, Chen Y, Jiang J, Zhou L, et al: PDLIM1 inhibits tumor
metastasis through activating hippo signaling in hepatocellular
carcinoma. Hepatology. 71:1643–1659. 2020. View Article : Google Scholar
|
|
39
|
Zhang JJ, Zhang QS, Li ZQ, Zhou JW and Du
J: Metformin attenuates PD-L1 expression through activating Hippo
signaling pathway in colorectal cancer cells. Am J Transl Res.
11:6965–6976. 2019.PubMed/NCBI
|
|
40
|
Takeda T, Banno K, Okawa R, Yanokura M,
Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K,
et al: ARID1A gene mutation in ovarian and endometrial cancers
(Review). Oncol Rep. 35:607–613. 2016. View Article : Google Scholar :
|
|
41
|
Takahashi K, Takenaka M, Okamoto A,
Bowtell DDL and Kohno T: Treatment Strategies for ARID1A-Deficient
ovarian clear cell carcinoma. Cancers (Basel). 13:17692021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Winarto H, Tan MI, Sadikin M and Wanandi
SI: ARID1A expression is down-regulated by oxidative stress in
endometriosis and endometriosis-associated ovarian cancer. Transl
Oncogenomics. 9:11772727166898182017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kawahara N, Yamada Y and Kobayashi H:
CCNE1 is a putative therapeutic target for ARID1A-Mutated ovarian
clear cell carcinoma. Int J Mol Sci. 22:58692021. View Article : Google Scholar : PubMed/NCBI
|
